Shane Fitzwater - Neogen Vice President Animal Safety Operations
| NEOG Stock | USD 12.02 0.43 3.45% |
President
Mr. Shane M. Fitzwater is the Vice President, Animal Safety Operations of the Company since April 2018. In his role, Mr. Fitzwater is responsible for the manufacturing, quality systems, supply chain, shipping and warehousing for our domestic biosecurity operations. Prior to joining Neogen, he spent 18 years in positions of increasing responsibility at Ecolab, Inc., including five years as Ecolabs vice president of supply chain, global specialty sector since 2018.
| Age | 43 |
| Tenure | 6 years |
| Address | 620 Lesher Place, Lansing, MI, United States, 48912-1595 |
| Phone | 517 372 9200 |
| Web | https://www.neogen.com |
Neogen Management Efficiency
The company has return on total asset (ROA) of 0.0179 % which means that it generated a profit of $0.0179 on every $100 spent on assets. This is way below average. Neogen's management efficiency ratios could be used to measure how well Neogen manages its routine affairs as well as how well it operates its assets and liabilities. The Neogen's current Return On Tangible Assets is estimated to increase to -0.02. The current Return On Capital Employed is estimated to decrease to 0.01. At this time, Neogen's Other Current Assets are most likely to increase significantly in the upcoming years. The Neogen's current Total Current Assets is estimated to increase to about 707.5 M, while Other Assets are projected to decrease to roughly 16.6 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Stephen Williamson | Thermo Fisher Scientific | 57 | |
| Mark Beaudouin | Waters | 63 | |
| William Daniel | Danaher | 53 | |
| Samraat Raha | Agilent Technologies | 51 | |
| Sherry Buck | Waters | 55 | |
| Marcel Roche | Guardant Health | N/A | |
| Mark Stevenson | Thermo Fisher Scientific | 57 | |
| Michael Boxer | Thermo Fisher Scientific | 58 | |
| Terrance Kelly | Waters | 54 | |
| Andrew Thomson | Thermo Fisher Scientific | 49 | |
| Jacquie Ross | Illumina | N/A | |
| Matthew McGrew | Danaher | 52 | |
| Charles Dadswell | Illumina | 65 | |
| Michael Tang | Agilent Technologies | 50 | |
| Patrick Kaltenbach | Agilent Technologies | 53 | |
| James Ditkoff | Danaher | 67 | |
| Paul Bianchi | Illumina | 53 | |
| Daniel Raskas | Danaher | 54 | |
| Jonathan Seaton | Illumina | N/A | |
| Robert Carson | Waters | 46 | |
| Sam Samad | Illumina | 48 | |
Management Performance
| Return On Equity | 5.0E-4 | ||||
| Return On Asset | 0.0179 |
Neogen Leadership Team
Elected by the shareholders, the Neogen's board of directors comprises two types of representatives: Neogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neogen. The board's role is to monitor Neogen's management team and ensure that shareholders' interests are well served. Neogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Crowder, Independent Director | ||
| Steven Quinlan, CFO, Principal Accounting Officer, VP and Secretary | ||
| Charles Fischer, Independent Director | ||
| Stewart Bauck, Vice President - Agrigenomics | ||
| James Herbert, Chairman and CEO | ||
| Daniel Kephart, Chief Science Officer | ||
| Terri Morrical, VP of Animal Safety Operations | ||
| Mark Mozola, Vice President - Research & Development | ||
| David Naemura, Chief Officer | ||
| Jack Parnell, Lead Independent Director | ||
| Darci Vetter, Independent Director | ||
| Jennifer Rice, Vice President & Senior Research Director | ||
| Jason Lilly, Vice President - Corporate Development | ||
| Joseph Corbett, Vice President Animal Safety Sales & Operations | ||
| James Tobin, Independent Director | ||
| William Boehm, Independent Director | ||
| Dwight Schroedter, Vice President Animal Safety Manufacturing | ||
| James Borel, Independent Director | ||
| Julie Mann, VP Officer | ||
| Kenneth Kodilla, Vice President - Manufacturing | ||
| Amy Rocklin, Chief Secretary | ||
| Robert Donofrio, Vice President - Food Safety Research and Development | ||
| Shane Fitzwater, Vice President Animal Safety Operations | ||
| Douglas Jones, COO VP | ||
| Clayton Yeutter, Independent Director | ||
| Jerome Hagedorn, Vice President - food safety operations | ||
| Bruce Papesh, Independent Director | ||
| Richard Calk, President COO | ||
| Bill Waelke, Head Relations | ||
| Edward Bradley, VP of Food Safety Operations | ||
| Melissa Herbert, Vice President - Support Services | ||
| Sarah Demey, Administrative Manager | ||
| Thomas Reed, Independent Director | ||
| Ronald Green, Director | ||
| John Adent, CEO President |
Neogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 5.0E-4 | ||||
| Return On Asset | 0.0179 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 3.43 B | ||||
| Shares Outstanding | 216.61 M | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 99.90 % | ||||
| Number Of Shares Shorted | 17.66 M | ||||
| Price To Earning | 13.36 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neogen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Neogen Stock please use our How to Invest in Neogen guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Neogen Stock analysis
When running Neogen's price analysis, check to measure Neogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neogen is operating at the current time. Most of Neogen's value examination focuses on studying past and present price action to predict the probability of Neogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neogen's price. Additionally, you may evaluate how the addition of Neogen to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is Neogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neogen. If investors know Neogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.86) | Earnings Share 0.02 | Revenue Per Share 4.293 | Quarterly Revenue Growth 0.048 | Return On Assets 0.0179 |
The market value of Neogen is measured differently than its book value, which is the value of Neogen that is recorded on the company's balance sheet. Investors also form their own opinion of Neogen's value that differs from its market value or its book value, called intrinsic value, which is Neogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neogen's market value can be influenced by many factors that don't directly affect Neogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.